[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577091":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":26,"responsibleParty":54,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":70,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Cornary plaque analysis group",null,"Patients with CCS or NSTE-ACS, who have marginal or obstructive lesions (DS 40% - 90%) detected by CCTA or ICA, will be consecutively enrolled. OCT, with or without other intracoronary imaging modalities including IVUS and NIRS, will be performed to classify plaque types and precisely measure plaque burden and other geometric parameters. Plasma samples will be collected on the day of angiography in all patients after overnight fasting.",[13],{"name":14,"affiliation":5,"role":15},"Ruiyan Zhang, M.D.,Ph.D.","STUDY_DIRECTOR",[17,23],{"name":18,"role":19,"phone":20,"phoneExt":21,"email":22},"Xiao Qun Wang, M.D.,Ph.D.","CONTACT","+86 21 64370045","671605","xiaoqun_wang@hotmail.com",{"name":24,"role":19,"phone":20,"phoneExt":21,"email":25},"Shuo Feng, M.D.,Ph.D.","fengshuorv@hotmail.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Ruijin Hospital, Shanghai Jiaotong University School of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.45806,31.22222,{"lat":39,"lon":38},[42,46,49,52],{"name":43,"role":19,"phone":44,"phoneExt":10,"email":45},"Jian Li, BS","0086 021 64370045","ruijincrc@126.com",{"name":47,"role":48,"phone":10,"phoneExt":10,"email":10},"Ruiyan Zhang, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",{"name":50,"role":51,"phone":10,"phoneExt":10,"email":10},"Xiaoqun Wang, M.D., Ph.D.","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":10,"phoneExt":10,"email":10},"Shuo Feng, M.D.,Ph,D,",{"type":48,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"RUIYAN ZHANG","Director of Cardiology, Director of cardiovascular catherization lab, Principle Investigator Affiliation: Ruijin Hospital","100577091","risk-evaluation-by-coronary-imaging-and-artificial-intelligence-based-functional-analyzing-techniques---iv-100577091",false,"NCT06793787","Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV","Risk Evaluation by Coronary Imaging and Artificial Intelligence-Based Functional Analyzing Techniques: Plasma Proteomic Profiles of Atheroma Classified by Intracoronary Imaging.","RECOGNIZE-IV","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with CCS or NSTE-ACS\n* Receive CCTA scan or ICA, with marginal lesions (DS between 40%-69%) or obstructive lesions (DS ≥70% or CT-FFR\u002FFFR \\\u003C0.8) in major coronary arteries\n* Receive invasive coronary angiography and OCT, with or without other intracoronary imaging techniques such as IVUS and NIRS\n\nExclusion Criteria:\n\n* Receive percutaneous coronary intervention (PCI) within 6 months\n* Prior history of myocardial infarction or heart failure\n* Prior history of coronary artery bypass graft (CABG)\n* Abnormal liver function (serum alanine aminotransferase \\[ALT\\] level exceeding 3 times the upper limit of normal) or abnormal kidney function (eGFR ≤30%)\n* Familial hypercholesterolemia\n* Estimated survival ≤ 1 year\n* Malignant tumor\n* Pregnant or lactation, or have the intention to give birth within one year\n* Poor compliance, unable to follow-up","ALL","18 Years",{"count":68,"type":69},200,"ESTIMATED","24 Months","OBSERVATIONAL","This study is a single-center, prospective cohort study. The study is designed to identify novel circulating biomarkers for early prediction of high-risk coronary plaques. Patients diagnosed with chronic coronary syndrome (CCS) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS), with marginal lesions or obstructive lesions in major coronary arteries detected by noninvasive coronary CT angiography (CCTA) or invasive coronary angiography (ICA), will be consecutively enrolled. Optical coherence tomography (OCT), with or without other intracoronary imaging modalities such as intravascular ultrasound (IVUS) and near infrared spectroscopy (NIRS), will be performed. Liquid chromatography-mass spectrometry (LC-MS\u002FMS), bioinformatic analysis, and machine learning methods will be performed to characterize plasma proteomic profiles. The cohort will be followed-up every 3 months for 2 years. The association of novel biomarkers with the occurrence of major adverse cardiovascular events (MACEs) will be examined.",[74,75,76,77],"Coronary Artery Disease","Coronary Atheroscleroses","Acute Coronary Syndromes (ACS)","Chronic Coronary Syndrome",[79,80,81,82,83],"Acute coronary syndrome","Chronic coronary syndrome","Coronary vulnerable plaque","intracoronary imaging","coronary CT angiography","2025-01-21",{"date":86,"type":87},"2025-01-27","ACTUAL",{"date":89,"type":87},"2024-07-01",{"date":91,"type":69},"2027-12-31",{"name":5,"class":6},1]